|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 2013年美国心脏病学会/美国心脏协会胆固醇管理指南在美国心脏病学实践中的应用显示文摘2013年美国心脏病学会/美国心脏协会(American College of Cardiology/American Heart Association,ACC/AHA)胆固醇管理指南建议在符合治疗标准的患者中采用中等强度至高强度他汀类药物治疗。该研究的目的在于审查2013年ACC/AHA指南在美国心脏病学实践中的应用情况。 | 刘莉 叶鹏 Pokharel Y Tang F Jones PG Nambi V Bittner VA Hira RS Nasir K Chan PS Maddox TM Oetgen WJ Heidenreich PA Borden WB Spertus JA Petersen LA Ballantyne CM Virani SS | 2017 | 中华高血压杂志2017，25，6： | 2 |
| 2 | 糖尿病、糖尿病前期与亚临床心肌损害发生率显示文摘众所周知,处于糖尿病前期者和糖尿病患者存在较高的心血管事件发生风险。然而,糖尿病前期和糖尿病与亚临床心肌损害发生间的关系尚不明确。方法与结果:应用高敏心肌肌钙蛋白T (highly sensitive cardiac troponin T hs-cTnT)分析,测定社区动脉粥样硬化风险研究中9331例受试者两个时间点(间隔6年)的心肌肌钙蛋白T(cardiac troponin T,cTnT)水平,所有受试者为无糖尿病或处于糖尿病前期,或糖尿病不伴心血管疾病(包括心电图检测出来的无临床症状的心肌梗死)。 | Selvin E Lazo M Chen Y Shen L Rubin J McEvoy JW Hoogeveen RC Sharrett AR Ballantyne CM Coresh J 刘莉 | 2014 | 中华高血压杂志2014，22，9： | 2 |
| 3 | Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study 显示文摘 | Ballantyne CM Hoogeveen RC Bang H Cotesh J Folsom AR Chambless LE | 2005 | Arch Intent Med2005，164，21： | 1 |
| 4 | Conditional risk factors for atherosclerosis显示文摘 | Kullo IJ Ballantyne CM | 2005 | Mayo Clin Proc2005，80，2： | 1 |
| 5 | Effect of ezetmibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: aprospective, randomized, double-blind trial显示文摘 | Ballantyne CM Houri J Notarbartolo A | 2003 | Circulation2003，107，19： | 1 |
| 6 | Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy 显示文摘 | Ballantyne CM Herd JA Ferlic LL | 1999 | Circulation1999，99，6： | 1 |
| 7 | Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syn- drome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin 显示文摘 | Ballantyne CM Pitt B Loscalzo J | 2013 | Am J Cardiol2013，111，4： | 1 |
| 8 | Myocardial infarction and remodeling in mice: effect of reperfusion显示文摘 | Michael LH Ballantyne CM Zachariah JP | 1999 | Am J Physiol1999，277，2： | 1 |
| 9 | Lipoprotein-asso- ciated phospholipase A2, high - sensitivity C - reactive protein, and risk for incident coronary heart disease in middle - aged men and women in the Atherosclerosis Risk in communities ( ARIC ) study 显示文摘 | Ballantyne CM Hoogeveen RC Bang H | 2004 | Circulation2004，109，7： | 1 |
| 10 | Effect of two intensivestatin regimens on progression of coronary disease 显示文摘 | Nicholls S J Ballantyne CM Chapman J | 2011 | N Engl J Med2011，365，22： | 1 |
| 11 | Pooled analyses of effects on C-Reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of Ezetimibe monotherapy or Ezetimibe added to baseline statin therapy显示文摘 | Pearson TA Ballantyne CM Vehri E | 2009 | Am J Cardiol2009，103，3： | 1 |
| 12 | Circulating adhesion molecules VCAM-1,ICAM-1 and E-selectin in carddiac atherosclerosis and incident coronary heart disease cases:The Atherosclerosis Risk In Communities (ARIC) study显示文摘 | Hwang SI Ballantyne CM Shrett AR | 1997 | Circulation1997，96，12： | 1 |
| 13 | Developing and assessing cardi- ovascular biomarkers显示文摘 | Dadu RT Nambi V Ballantyne CM | 2012 | Transl Res2012，159，4： | 1 |
| 14 | Eficiency and safety of rosuvastatin 40 mg alone and in combination with ezetimibe in patients at high risk of cardiovascular disease(results from the EXPLORER Study)显示文摘 | Ballantyne CM Weiss R Moceetti T | 2007 | Am J Cardiol2007，99，： | 1 |
| 15 | Efficacy and tolerability of fluvastatin extended-release delivery system:A pooled analysis显示文摘 | Ballantyne CM Pazzucconi F Xavier P | | 0，，02： | 1 |
| 16 | Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease显示文摘 | Schneck DW Knopp RH Ballantyne CM | 2003 | Am J Cardiol2003，91，1： | 1 |
| 17 | A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis显示文摘 | Chen SN Ballantyne CM Gotto AM Jr Tan Y Willerson JT Marian AJ | 2005 | J Am Coll Cardiol2005，45，10： | 1 |
| 18 | Dose compari- son study of the combination of ezetimibe and simvas- tatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia; the Vytorin Versus Atorvastatin (VYVA) study显示文摘 | Ballantyne CM Abate N Yuan Z | 2005 | Am Heart J2005，149，3： | 1 |
| 19 | Circulating adhesion molecules VCAM-1, ICAM-1, and Eselectin in carotid atheroselerosis and incident coronary heart disease cases: the Atheroselerosis Risk In Communities (AR IC) study 显示文摘 | HWANG SJ BALLANTYNE CM SHARRETT AR | 1997 | Circulation1997，96，12： | 1 |
| 20 | Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronery heart disase case: The Atherosclerosis Risk In Communities (ARIC) study显示文摘 | Hwang SJ Ballantyne CM Sharrett AR | 1997 | Circulation1997，96，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员